MIRM News and Press, Mirum Pharmaceuticals Inc. From 06/13/24

2024-06-13 06:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

- Data showcases sustained clinical benefit following seven years of LIVMARLI treatment in patients with Alagille syndrome - Long-term extension data from LIVMARLI PFIC studies highlight improvement in key liver markers and growth Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today annou...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the Goldman Sachs 45th Annual Global Healthca...

Positive opinion from CHMP based on Phase 3 MARCH study with highly statistically significant (p<0.0001) reduction in pruritus severity between LIVMARLI vs. placebo across all PFIC types studied. CHMP assessment concluded that LIVMARLI in PFIC brings significant clinical benefit over the e...

- Data showcases sustained clinical benefit following 7 years of LIVMARLI treatment in patients with Alagille syndrome - Long-term extension data from LIVMARLI PFIC studies highlight improvement in key liver markers and growth Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

2024-05-23 12:00:10 ET Joshua Schimmer from Cantor Fitzgerald issued a price target of $45.00 for MIRM on 2024-05-23 09:58:00. The adjusted price target was set to $45.00. At the time of the announcement, MIRM was trading at $25.745. The overall price target consensus is...

- Seven abstracts highlighting ALGS and PFIC data, including three oral presentations - Long-term extension data from Phase 3 MARCH-ON PFIC study presented at plenary session and selected among the highest scoring abstracts Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced da...

2024-05-12 16:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-11 14:25:17 ET Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Conference Call May 08, 2024, 04:30 PM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief Executive Officer Peter Radovich - President & C...